Update on progress with PD-1 and PD-L1 immunotherapies at ASCO 2013.
Access the ASCO 2013 Video Highlights Preview
Video interview at ASCO 2013 with Dr Susan O'Brien, Ashbel Smith Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center in Houston, in which she discusses many of the exciting new targeted therapies that are set to change the treatment of chronic lymphocytic leukemia (CLL).
Gilead announced they will file idelalisib in iNHL in 2nd half of 2014. Interim CLL data is also expected then.